4.8 Article

SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival

期刊

ONCOGENE
卷 30, 期 49, 页码 4887-4900

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2011.198

关键词

melanoma; p53; signaling; tumor biology

资金

  1. INSERM (Institut National de la Santeet de la Recherche Medicale)
  2. ARC (Association pour la Recherche sur le Cancer) [1136]

向作者/读者索取更多资源

Aberrant expression of Secreted Protein Acidic and Rich in Cysteine (SPARC)/osteonectin has been associated with an invasive tumor cell phenotype and poor outcome in human melanomas. Although it is known that SPARC controls melanoma tumorigenesis, the precise role of SPARC in melanoma cell survival is still unclear. Here, we show that SPARC has a cell-autonomous survival activity, which requires Akt-dependent regulation of p53. Suppression of SPARC by RNA interference in several human melanoma cells and xenografted A375 tumors triggers apoptotic cell death through the mitochondrial intrinsic pathway and activation of caspase-3. Cell death induced by depletion of SPARC is dependent on p53 and induction of Bax, and results in the generation of ROS. Stabilization of p53 in SPARC-depleted cells is associated with a decrease in Akt-mediated activating phosphorylation of MDM2. Inhibition of Akt signaling pathway is important for the observed changes as overexpression of constitutively active Akt protects cells against apoptosis induced by SPARC depletion. Conversely, increased expression of SPARC stimulates Akt and MDM2 phosphorylation, thus facilitating p53 degradation. Finally, we show that overexpression of SPARC renders cells more resistant to the p53-mediated cytotoxic effects of the DNA-damaging drug actinomycin-D. Our study indicates that SPARC functions through activation of Akt and MDM2 to limit p53 levels and that acquired expression of SPARC during melanoma development would confer survival advantages through suppression of p53-dependent apoptotic pathways. Oncogene (2011) 30, 4887-4900; doi: 10.1038/onc.2011.198; published online 20 June 2011

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, Maria Karagianni, Petra C. Schwalie, Laura Lauener, Eleni Maria Varypataki, Marine Richard, Esther Bommer, Johannes Sam, Stefanie Joller, Mario Perro, Floriana Cremasco, Leo Kunz, Emilio Yanguez, Tamara Husser, Ramona Schlenker, Marisa Mariani, Vinko Tosevski, Sylvia Herter, Marina Bacac, Inja Waldhauer, Sara Colombetti, Xavier Gueripel, Stephan Wullschleger, Melanie Tichet, Douglas Hanahan, Haydn T. Kissick, Stephane Leclair, Anne Freimoser-Grundschober, Stefan Seeber, Volker Teichgraber, Rafi Ahmed, Christian Klein, Pablo Umana

Summary: The study shows that PD1-IL2v can induce the differentiation of stem-like CD8(+) T cells into better effector cells by binding to PD-1, without the need for CD25 binding. PD1-IL2v has superior efficacy compared to PD-1 or PD-L1 blocking antibodies, as it avoids the accumulation of terminally differentiated and exhausted T cells.

NATURE (2022)

Article Immunology

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor- reactive CD8+T cells and reprogramming macrophages

Melanie Tichet, Stephan Wullschleger, Agnieszka Chryplewicz, Nadine Fournier, Rachel Marcone, Annamaria Kauzlaric, Krisztian Homicsko, Laura Codarri Deak, Pablo Umana, Christian Klein, Douglas Hanahan

Summary: PD1-IL2v is an engineered immunocytokine that delivers IL2v precisely to PD-1+ T cells in the tumor microenvironment, resulting in infiltration by stem-like CD8+ T cells and enhanced tumor regression and survival in mice. Combining PD1-IL2v with anti-PD-L1 improves therapeutic efficacy by reprogramming tumor-associated macrophages and enhancing T cell receptor immune repertoire diversity. These findings support the clinical evaluation of PD1-IL2v and anti-PD-L1 combination therapy in immunotherapy-resistant tumors infiltrated with PD-1+ stem-like T cells.

IMMUNITY (2023)

Article Oncology

SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity

Lindsay B. Alcaraz, Aude Mallavialle, Caroline Mollevi, Florence Boissiere-Michot, Hanane Mansouri, Joelle Simony-Lafontaine, Valerie Laurent-Matha, Thierry Chardes, William Jacot, Andrei Turtoi, Pascal Roger, Severine Guiu, Emmanuelle Liaudet-Coopman

Summary: The study reveals that SPARC expression in cancer-associated fibroblasts (CAF) is an independent prognostic marker of poor outcome in triple-negative breast cancer (TNBC). The fibroblast-secreted SPARC also has a tumor-promoting role by inhibiting TNBC cell adhesion and stimulating their motility and invasiveness.

INTERNATIONAL JOURNAL OF CANCER (2023)

Editorial Material Oncology

Novel Therapeutic Targets in Melanoma

Michael Cerezo, Stephane Rocchi

CANCERS (2023)

Article Clinical Neurology

Sphingosine-1 Phosphate Receptor Modulators Increase In Vitro Melanoma Cell Line Proliferation at Therapeutic Doses Used in Patients with Multiple Sclerosis

Caroline Ruetsch-Chelli, Darin T. T. Okuda, Fanny Rocher, Sophie Tartare-Deckert, Marcel Deckert, Christine Lebrun-Frenay

Summary: This study investigated the effects of four S1P(1)-RM drugs approved for managing multiple sclerosis on melanoma cell lines in vitro and found that these drugs can promote the proliferation of melanoma cells at therapeutic concentrations. Therefore, increased dermatologic surveillance should be considered for patients with multiple sclerosis receiving S1P(1)-RM treatments.

NEUROLOGY AND THERAPY (2023)

Letter Hematology

Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

Reinaldo Dal Bello, Kim Pacchiardi, Clementine Chauvel, Lionel Ades, Thorsten Braun, Justine Pasanisi, Elise Fournier, Celine Berthon, Emmanuelle Clappier, Emmanuel Raffoux, Delphine Lebon, Thomas Cluzeau, Christophe Roumier, Adriana Plesa, Karine Celli-Lebras, Herve Dombret, Claude Preudhomme, Stephanie Mathis, Alexandre Puissant, Claude Gardin, Raphael Itzykson

HEMASPHERE (2023)

Article Dermatology

Impact of house dust mite in vitiligo skin: environmental contribution to increased cutaneous immunity and melanocyte detachment

Hanene Bzioueche, Katia Boniface, Claire Drullion, Sandrine Marchetti, Berengere Chignon-Sicard, Laura Sormani, Stephane Rocchi, Julien Seneschal, Thierry Passeron, Meri K. Tulic

Summary: Vitiligo is an autoimmune disease characterized by melanocyte loss and white patches on the skin. This study demonstrates that house dust mite (HDM) can induce inflammatory responses and melanocyte detachment in vitiligo through protease activity. HDM may act as an external source of pathogen-associated molecular pattern molecules in vitiligo, and MMP-9 inhibitors could be potential therapeutic targets. Furthermore, studying specific vitiligo endophenotypes can help understand the environmental contribution to the disease.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Biochemistry & Molecular Biology

The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential

Kenji F. Shoji, Elsa Bayet, Sabrina Leverrier-Penna, Dahiana Le Devedec, Aude Mallavialle, Severine Marionneau-Lambot, Florian Rambow, Raul Perret, Aurelie Joussaume, Roselyne Viel, Alain Fautrel, Amir Khammari, Bruno Constantin, Sophie Tartare-Deckert, Aubin Penna

Summary: Melanoma, a highly aggressive cancer, is driven by aberrant cell motility behaviors and the ability to rapidly metastasize. This study reveals the prominent expression of the plasma membrane TRPV2 calcium channel in melanoma tumors, directly linked to metastatic dissemination. TRPV2 activity confers migratory and invasive potentials in both in vitro and in vivo settings, while silencing TRPV2 in highly metastatic melanoma cells prevents aggressive behavior. The TRPV2 channel, localized at the leading edge of invasive melanoma cells, regulates calcium-mediated activation of calpain and subsequent cleavage of talin, along with F-actin organization. Overexpression of TRPV2 in human melanoma tissues is associated with advanced malignancy and poor prognosis, suggesting its potential as a biomarker. By controlling adhesion and motility, the mechanosensitive TRPV2 channel offers a new therapeutic option for migrastatics in metastatic melanoma treatment.

EMBO REPORTS (2023)

Article Biochemistry & Molecular Biology

Ceramide AD™ Restores Skin Integrity and Function following Exposure to House Dust Mite

Hanene Bzioueche, Myriam Tamelghaghet, Berengere Chignon-Sicard, Noemie Bazile, Pauline Hauchecorne, Maria Barbero Calderon, Pauline Meunier, Stephane Rocchi, Thierry Passeron, Meri K. Tulic

Summary: Ceramides are crucial for the barrier function of normal skin. Reduced ceramide levels are associated with atopic dermatitis. This study examined the impact of house dust mite (HDM) on skin integrity and the effect of different ceramides on HDM-induced skin damage. The presence of Ceramide AD (TM) in a cream inhibited HDM-induced damage and restored skin barrier function.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Oncology

The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance

Serena Diazzi, Sophie Tartare-Deckert, Marcel Deckert

Summary: Advanced cutaneous melanoma is the deadliest form of skin cancer, and targeted therapies and immune checkpoint blockade therapies have revolutionized its treatment. However, therapy-driven resistance remains a significant challenge. Recent studies have shown that phenotypic plasticity of melanoma cells, particularly their ability to adapt mechanically, is a key factor in treatment resistance and tumor relapse. Targeting dedifferentiated cells and mechanotransduction pathways in the extracellular matrix (ECM) may hold promise in overcoming melanoma cross-resistance.

ONCOGENESIS (2023)

Article Oncology

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia

Kevin H. Lin, Justine C. Rutter, Abigail Xie, Shane T. Killarney, Camille Vaganay, Chaima Benaksas, Frank Ling, Gaetano Sodaro, Paul-Arthur Meslin, Christopher F. Bassil, Nina Fenouille, Jacob Hoj, Rachel Washart, Hazel X. Ang, Christian Cerda-Smith, Paul Chaintreuil, Arnaud Jacquel, Patrick Auberger, Antoine Forget, Raphael Itzykson, Min Lu, Jiaxing Lin, Mariaelena Pierobon, Zhecheng Sheng, Xinghai Li, Ashutosh Chilkoti, Kouros Owzar, David A. Rizzieri, Timothy S. Pardee, Lina Benajiba, Emanuel Petricoin, Alexandre Puissant, Kris C. Wood

Summary: The XPO1 inhibitor Selinexor activates PI3Ky-dependent AKT signaling in AML via upregulation of P2RY2, leading to positive antileukemic effects. Inhibiting this signaling pathway enhances the efficacy of Selinexor in AML.

NATURE CANCER (2022)

Article Multidisciplinary Sciences

Screening of ETO2-GLIS2-induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia

Salima Benbarche, Cecile K. Lopez, Eralda Salataj, Zakia Aid, Cecile Thirant, Marie-Charlotte Laiguillon, Severine Lecourt, Yannis Belloucif, Camille Vaganay, Marion Antonini, Jiang Hu, Alexandra da Silva Babinet, Delphine Ndiaye-Lobry, Bryann Pardieu, Arnaud Petit, Alexandre Puissant, Julie Chaumeil, Thomas Mercher, Camille Lobry

Summary: This study reveals that fusion oncogenes like ETO2-GLIS2 can induce the activation of Super Enhancers (SEs) that regulate essential gene modules synergizing for leukemia progression, promoting the growth and survival of leukemia cells.

SCIENCE ADVANCES (2022)

暂无数据